Discover
MGX
Metagenomi Therapeutics, Inc.
1.19
2 x 0.86
1 x 1.51
bid
ask
-
0.02
1.57%
11:25 AM
timesize
| Ytd | -26.48% | |
| 1y | -26.02% |
1.18
day range
1.22
1.13
52 week range
3.95
| Open | 1.22 | Prev Close | 1.21 | Low | 1.18 | High | 1.22 | Mkt Cap | 45.12M |
| Vol | 161.67K | Avg Vol | 167.31K | EPS | -2.29 | P/E | N/A | Forward P/E | -1.38 |
| Beta | N/A | Short Ratio | 0.60 | Inst. Own | 34.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.32 | 200-d Avg | 1.72 | 1yr Est | 18.40 |
| Income Statement | |||
| Total Revenue | 1.25M | ||
| Revenues (USD) | 1.25M | ||
| Gross Profit | 1.25M | ||
| Operating Expenses | 25.84M | ||
| Research and Development Expense | 19.30M | ||
| Selling, General and Administrative Expense | 6.54M | ||
| Operating Income | -24.59M | ||
| Income Tax Expense | 10.00K | ||
| Net Income | -23.06M | ||
| Net Income Common Stock | -23.06M | ||
| Net Income Common Stock (USD) | -23.06M | ||
| Consolidated Income | -23.06M | ||
| Earnings per Basic Share | -0.61 | ||
| Earnings per Basic Share (USD) | -0.61 | ||
| Earnings per Diluted Share | -0.61 | ||
| Earning Before Interest & Taxes (EBIT) | -23.05M | ||
| Earning Before Interest & Taxes (USD) | -23.05M | ||
| Weighted Average Shares | 37.58M | ||
| Weighted Average Shares Diluted | 37.58M | ||
| Balance Sheet | |||
| Cash and Equivalents | 29.70M | ||
| Cash and Equivalents (USD) | 29.70M | ||
| Investments | 117.01M | ||
| Investments Current | 114.86M | ||
| Investments Non-Current | 2.15M | ||
| Current Assets | 144.56M | ||
| Property, Plant & Equipment Net | 44.92M | ||
| Total Assets | 196.95M | ||
| Debt Current | 6.11M | ||
| Total Debt | 39.19M | ||
| Current Liabilities | 22.50M | ||
| Debt Non-Current | 33.08M | ||
| Total Liabilities | 59.17M | ||
| Accumulated Retained Earnings (Deficit) | -333.93M | ||
| Accumulated Other Comprehensive Income | -44.00K | ||
| Shareholders Equity | 137.79M | ||
| Shareholders Equity (USD) | 137.79M | ||
| Assets Non-Current | 52.40M | ||
| Total Debt (USD) | 39.19M | ||
| Deferred Revenue | 10.94M | ||
| Liabilities Non-Current | 36.67M | ||
| Trade and Non-Trade Payables | 2.40M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.61M | ||
| Net Cash Flow from Financing | -27.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -17.22M | ||
| Capital Expenditure | -25.00K | ||
| Issuance (Repayment) of Debt Securities | -27.00K | ||
| Net Cash Flow from Investing | 3.99M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.01M | ||
| Net Cash Flow from Operations | -21.17M | ||
| Share Based Compensation | 2.55M | ||